? ? Functional mitral regurgitation (MR) is a common complication of ischemic heart disease. Two large clinical trials confirmed an adverse effect of functional MR on survival after a heart attack. However, studies in heart failure are small and mainly limited to patients with nonischemic cardiomyopathy. Recent animal studies have challenged the traditional concept that functional MR is a consequence of mitral annular dilation, instead suggesting that functional MR is due to leaflet tethering by outward expansion of the left ventricular wall (i.e. LV remodeling). This has critical implications regarding the correct surgical approach to correcting functional MR. TO date, no large prospective studies have examined the mechanism(s) of functional MR in ischemic cardiomyopathy, nor has the interaction between mechanism and prognosis been explored. This is a crucial knowledge gap because 1) 70% of heart failure cases are caused by ischemic heart disease, and 2) functional MR occurs in around 60% of patients with ischemic cardiomyopathy. This proposal aims to fill these gaps by defining the mechanism(s) of functional MR by transesophageal echocardiography in a large clinical trial of patients with ischemic cardiomyopathy. The following specific aims will be addressed: ? ? Aim 1: To define the mechanism(s) of functional MR in ischemic cardiomyopathyAim 2: To define the effect of therapy on mechanism and severity of functional MRAim 3: To evaluate the effect of functional MR on prognosis is ischemic cardiomyopathyAim 4: To evaluate the effect of myocardial viability on functional MR and its response to treatment ? ? We propose to accomplish these aims as a ancillary study to the Surgical Treatment of Ischemic Heart Failure (STICH) Trial. The STICH Trial will compare surgical revascularization versus medical therapy for treatment of heart failure in 2800 patients with ischemic cardiomyopathy, and therefore affords a unique opportunity to investigate the mechanism(s) of functional MR. Despite its known clinical utility of assessing the mechanism and severity of MR, TEE is not currently included in STICH.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL072430-03
Application #
6771737
Study Section
Special Emphasis Panel (ZHL1-CSR-A (S1))
Program Officer
Sopko, George
Project Start
2002-09-30
Project End
2006-07-31
Budget Start
2004-08-01
Budget End
2005-07-31
Support Year
3
Fiscal Year
2004
Total Cost
$105,050
Indirect Cost
Name
Baylor Research Institute
Department
Type
DUNS #
145745022
City
Dallas
State
TX
Country
United States
Zip Code
75204
Grayburn, Paul A; She, Lilin; Roberts, Brad J et al. (2015) Comparison of Transesophageal and Transthoracic Echocardiographic Measurements of Mechanism and Severity of Mitral Regurgitation in Ischemic Cardiomyopathy (from the Surgical Treatment of Ischemic Heart Failure Trial). Am J Cardiol 116:913-8
Feldman, Arthur M; She, Lilin; McNamara, Dennis M et al. (2015) Genetic variants are not associated with outcome in patients with coronary artery disease and left ventricular dysfunction: results of the Genetic Substudy of the Surgical Treatment for Ischemic Heart Failure (STICH) trials. Cardiology 130:69-81
Shimoda, Masayuki; Chen, Shuyuan; Noguchi, Hirofumi et al. (2014) A new method for generating insulin-secreting cells from human pancreatic epithelial cells after islet isolation transformed by NeuroD1. Hum Gene Ther Methods 25:206-19
Golba, Krzysztof; Mokrzycki, Krzysztof; Drozdz, Jaroslaw et al. (2013) Mechanisms of functional mitral regurgitation in ischemic cardiomyopathy determined by transesophageal echocardiography (from the Surgical Treatment for Ischemic Heart Failure Trial). Am J Cardiol 112:1812-8
Feldman, Arthur M; Mann, Douglas L; She, Lilin et al. (2013) Prognostic significance of biomarkers in predicting outcome in patients with coronary artery disease and left ventricular dysfunction: results of the biomarker substudy of the Surgical Treatment for Ischemic Heart Failure trials. Circ Heart Fail 6:461-72
Shimoda, M; Chen, S; Noguchi, H et al. (2010) In vivo non-viral gene delivery of human vascular endothelial growth factor improves revascularisation and restoration of euglycaemia after human islet transplantation into mouse liver. Diabetologia 53:1669-79